LONDON (Alliance News) - Redx Pharma PLC on Tuesday said it has reached pre-clinical development stage on an anti-infective compound designed to treat Methicillin-Resistant Staphylococcus Aureus.
MRSA is a bacterium which can cause potentially lethal infections in humans.
The discovery has been made as part of Redx's commercial partnership with the NHS, working with The Royal Liverpool and Broadgreen University Hospitals Trust.
Redx said the compound demonstrates excellent oral efficacy and has the potential to be easily administered both in the wider community and in a hospital setting. This is in contrast to current treatment for MRSA, which typically requires in-hospital treatment with antibiotics available only in an injectable form, the company added.
"We're very excited by the possibilities presented by the discovery of this compound, which could have global implications in the fight against drug resistant infections. The lack of new drugs to target drug-resistant infections is a critical issue, as is finding more efficient ways to administer them to patients," said Neil Murray, Redx's chief executive.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
